KG&L Capital Management LLC Has $858,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

KG&L Capital Management LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 29.1% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,753 shares of the medical research company's stock after selling 1,128 shares during the period. KG&L Capital Management LLC's holdings in Amgen were worth $858,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after purchasing an additional 5,226 shares during the last quarter. IFP Advisors Inc lifted its holdings in Amgen by 6.2% during the 4th quarter. IFP Advisors Inc now owns 6,102 shares of the medical research company's stock worth $1,591,000 after buying an additional 357 shares during the period. Pine Valley Investments Ltd Liability Co grew its position in shares of Amgen by 4.3% in the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 4,913 shares of the medical research company's stock valued at $1,280,000 after buying an additional 204 shares during the last quarter. FFT Wealth Management LLC increased its stake in shares of Amgen by 3.6% in the fourth quarter. FFT Wealth Management LLC now owns 1,402 shares of the medical research company's stock valued at $365,000 after buying an additional 49 shares during the period. Finally, Lake Street Advisors Group LLC increased its stake in shares of Amgen by 84.8% in the fourth quarter. Lake Street Advisors Group LLC now owns 12,746 shares of the medical research company's stock valued at $3,322,000 after buying an additional 5,848 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on AMGN. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $305.00 price objective on shares of Amgen in a research note on Tuesday. William Blair restated an "outperform" rating on shares of Amgen in a research report on Tuesday. Mizuho upped their price objective on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research note on Wednesday, May 7th. Johnson Rice set a $294.00 target price on shares of Amgen in a research note on Wednesday, March 5th. Finally, Bank of America boosted their target price on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a report on Wednesday, March 5th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $309.22.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $280.35 on Thursday. The stock has a market cap of $150.75 billion, a price-to-earnings ratio of 25.58, a PEG ratio of 2.51 and a beta of 0.51. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The firm's 50-day simple moving average is $280.99 and its 200 day simple moving average is $286.00.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping the consensus estimate of $4.18 by $0.72. The firm had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The company's quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the business posted $3.96 earnings per share. As a group, research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Insider Activity at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president now owns 8,162 shares in the company, valued at $2,364,368.16. This represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.76% of the stock is currently owned by insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.